Mereo BioPharma Group plc
MREO
$2.74
$0.2811.38%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 12.67% | 4.05% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -25.05% | 60.70% | |||
| Operating Income | 25.05% | -60.70% | |||
| Income Before Tax | -82.90% | 53.03% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -82.90% | 53.03% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -82.90% | 53.03% | |||
| EBIT | 25.05% | -60.70% | |||
| EBITDA | 25.28% | -61.79% | |||
| EPS Basic | -80.66% | 53.29% | |||
| Normalized Basic EPS | -80.63% | 53.37% | |||
| EPS Diluted | -80.66% | 53.29% | |||
| Normalized Diluted EPS | -80.63% | 53.37% | |||
| Average Basic Shares Outstanding | 1.19% | 0.64% | |||
| Average Diluted Shares Outstanding | 1.19% | 0.64% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||